Florida 2024 2024 Regular Session

Florida Senate Bill S1582 Analysis / Analysis

Filed 02/07/2024

                    The Florida Senate 
BILL ANALYSIS AND FISCAL IMPACT STATEMENT 
(This document is based on the provisions contained in the legislation as of the latest date listed below.) 
Prepared By: The Professional Staff of the Committee on Health Policy  
 
BILL: CS/SB 1582 
INTRODUCER:  Health Policy Committee and Senator Rodriguez 
SUBJECT:  Department of Health 
DATE: February 7, 2024 
 
 ANALYST STAFF DIRECTOR  REFERENCE  	ACTION 
1. Rossitto-Van 
Winkle 
 
Brown 
 
HP 
 
Fav/CS 
2.     AHS   
3.     FP  
 
Please see Section IX. for Additional Information: 
COMMITTEE SUBSTITUTE - Substantial Changes 
 
I. Summary: 
CS/SB 1582 amends numerous statutory provisions relating to the Department of Health (DOH) 
and creates a new program within the department. The bill: 
 Amends s. 381.0101, F.S., to create a new profession, the environmental health technician 
(EHT) and requires the DOH, in conjunction with the Department of Environmental 
Protection (DEP), to adopt rules that establish minimum standards for education, training, 
and experience required for certification relating to supervised employment in a department 
in the areas of onsite sewage treatment and disposal, septic inspection, permitting, 
examinations, continuing education, and renewals; 
 Creates the Andrew John Anderson Pediatric Rare Disease Grant Program to advance 
research and cures for rare pediatric diseases by awarding grants through a competitive, peer-
reviewed process; 
 Amends s. 383.14, F.S., to require defined health care practitioners present at a birth, or 
responsible for primary care during the neonatal period, to administer newborn metabolic 
screenings. The bill requires that health care practitioners responsible for administering 
newborn screenings to send all specimen cards to the State Public Health Laboratory, adds 
genetic counselors to health care practitioners who may receive state lab results, and deletes 
obsolete provisions; 
 Amends s. 383.145, F.S., to standardize the requirements for newborn, infant, and toddler 
hearing screening at hospitals, licensed birth facilities, and birth centers; expands physician-
ordered screening to include infants and toddlers to ensure timely congenital 
REVISED:   BILL: CS/SB 1582   	Page 2 
 
cytomegalovirus (CMV) screening; and defines toddlers as a child from 12 to 36 months of 
age; 
 Amends s. 383.147, F.S., to require the DOH to notify parents or guardians of the ability to 
opt-out of the state’s sickle cell registry by submitting a DOH form and adds a provision for 
allowing Florida residents to opt-in to the registry; and 
 Creates s. 383.148, F,S., to standardize requirements, and clarify the purpose, of prenatal 
high-risk pregnancy and postnatal infant mortality and morbidity screening for environmental 
risk factors unless the pregnant woman or parent/guardian, as applicable, objects to the 
screening manner prescribed the DOH. 
 
The bill provides an effective date of July 1, 2024. 
II. Present Situation: 
The Department of Health 
The Department of Health (DOH) is responsible for the state’s public health system, which must 
be designed to promote, protect, and improve the health of all people in the state.
1
 
 
Environmental Health Professionals 
Environmental health is that segment of public health work which deals with the examination of 
those factors in the human environment which may adversely impact on the health status of an 
individual or the public.
2
 An environmental health professional (EHP) is a person employed or 
assigned the responsibility of assessing the environmental health or sanitary conditions, as 
defined by the DOH, within a building, on an individual’s property, or within the community at 
large, and who has the knowledge, skills, and abilities to carry out these tasks. An EHP may be 
field, supervisory, or an administrative staff member.
3
 
 
A person may not perform environmental health or sanitary evaluations in any primary program 
area of environmental health without being certified by the DOH as competent to perform such 
evaluations, with several exceptions.
4
 Those exceptions include: 
 Persons performing inspections of public food service establishments licensed under ch. 509, 
F.S., or 
 Persons performing site evaluations in order to determine proper placement and installation 
of onsite wastewater treatment and disposal systems who have successfully completed a 
DOH-approved soils morphology course and who are working under the direct responsible 
charge of an engineer licensed under ch. 471, F.S. 
 
                                                
1
 Section 381.001, F.S. 
2
 Section 381.010,(1)(c), F.S. 
3
 Section 381.010,(1)(d), F.S. 
4
 Section 381.010,(2), F.S. This section does not apply to persons performing inspections of public food service 
establishments licensed under ch. 509, F.S.; or persons performing site evaluations in order to determine proper placement 
and installation of onsite wastewater treatment and disposal systems who have successfully completed a DOH-approved soils 
morphology course and who are working under the direct responsible charge of an engineer licensed under ch. 471, F.S.  BILL: CS/SB 1582   	Page 3 
 
A person seeking certification as an EHP in any primary program area must:
5
 
 Be employed or assigned to provide environmental health services in any primary 
environmental health program;
6
 
 Submit the application and application fee to the DOH for the primary environmental health 
program in which the applicant seeks certification; and 
 Submit an official college transcript evidencing a bachelor’s degree from an accredited 
college or university with major coursework in environmental health, environmental science, 
or a physical or biological science. 
 
Within 45 days of the DOH’s receipt of the completed application, the applicant will receive 
notice of whether he or she meets the general requirements and is eligible for certification and if 
eligible, will receive a schedule for classes and program examinations. 
 
Applicants seeking certification in the Onsite Sewage Treatment and Disposal System Program 
must: 
 Complete 24 hours of the DOH-provided pre-certification coursework which includes 
training and testing on soil classification, system design and theory, system material and 
construction standards, and regulatory requirements; and 
 Pass the examinations administered by the DOH with a minimum passing score of 70 
percent.
7
 
 
Applicants seeking certification in the Food Protection Program must: 
 Complete 24 hours of the DOH-provided pre-certification coursework which includes 
training and testing on food microbiology, foodborne illness investigations, and basic hazard 
analysis and critical control points (HACCP); and 
 Pass the pre-certification coursework and certification examinations administered by the 
DOH with a minimum passing score of 70 percent.
8
 
 
The DOH currently employs 448 certified environmental health professionals (CEHP), most of 
whom are housed in county health departments (CHD) to perform health evaluations at public 
food establishments and sanitary evaluations on private and business properties where onsite 
wastewater treatment and disposal systems are in use. Other CEHPs supervise CHD 
environmental health teams or work within the Bureau of Environmental Public Health to direct 
statewide programs.
9
 
 
Section 381.0065, F.S., gives the DEP authority to inspect onsite sewage treatment and disposal 
systems (OSTDS), which CHD staff complete for DEP as outlined in a five-year interagency 
agreement required by Section 2 of Chapter 2020-150, Laws of Florida. It also authorizes four 
                                                
5
 Fla. Admin. Code R. 64E-18.003(2023). 
6
 Section 381.0101(2), F.S. 
7
 Fla. Admin. Code R. 64E-18.003(6)(2023). 
8
 Fla. Admin. Code R. 64E-18.003(7)(2023). 
9
 This excludes establishments licensed under ch. 509, F.S., which operate under separate standards. See, Department of 
Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate Committee on Health 
Policy).  BILL: CS/SB 1582   	Page 4 
 
groups to complete private provider septic inspections, including two that do not require a four-
year degree.
10
 
 
Section 381.0101(4), F.S., sets out the standards for certification and grants the DOH the 
authority to adopt rules that establish definitions of terms and minimum standards of education, 
training, or experience for those seeking certification. CEHPs must earn certification from the 
DOH to perform evaluations of environmental or sanitary conditions in any program area of 
environmental health. However, due to the four-year degree requirement for environmental 
health professionals under section 381.0101(4)(e), F.S., CHDs are experiencing a shortage of 
qualified applicants for the OSTDS and food hygiene programs.
11
 
 
Rare Diseases 
The federal Orphan Drug Act defines a rare disease as any condition that nationally affects fewer 
than 200,000 people. Over 7,000 rare diseases affect more than 30 million people in the U.S. 
Many rare conditions are life-threatening and most do not have treatments. Drug, biologic, and 
device development in rare diseases is challenging for many reasons, including the complex 
biology and the lack of understanding of the natural history of many rare diseases. The inherently 
small population of patients with a rare disease can also make conducting clinical trials difficult. 
 
Since the Orphan Drug Act was signed into law in 1983, the federal Food and Drug 
Administration (FDA) has approved hundreds of drugs for rare diseases, but most rare diseases 
do not have FDA-approved treatments. The FDA works with many people and groups, such as 
patients, caregivers, and drug and device manufactures, to support rare disease product 
development. So, while the individual diseases may be rare, the total number of people impacted 
by a rare disease is larger.
12
 
 
Rare diseases include genetic disorders, infectious diseases, cancers, and various other pediatric 
and adult conditions. A rare disease can affect anyone at any point in their life, and can be acute 
or chronic. It is estimated that 80 percent or more of rare diseases are genetic. For genetic rare 
diseases, genetic testing is often the only way to make a definitive diagnosis. 
 
Rare diseases present a fundamentally different array of challenges compared to those of more 
common diseases Often patients are set on a “diagnostic odyssey,” in order to determine the 
cause of their symptoms as they seek treatment in health care settings where their condition may 
have never been seen before.
13
 
 
                                                
10
 Department of Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate 
Committee on Health Policy). 
11
 Id. 
12
 United States Food and Drug Administration, Rare Diseases at FDA, available at https://www.fda.gov/patients/rare-
diseases-fda (last visited Jan. 31, 2024). 
13
 Department of Health, Rare Disease Advisory Council: Legislative Report, Fiscal Year 2022-2023 (2023). Available at 
https://www.floridahealth.gov/provider-and-partner-resources/rdac/_documents/RDACLegislativeReport2023Final_Draft.pdf 
(last visited Jan. 31, 2024).  BILL: CS/SB 1582   	Page 5 
 
Rare Pediatric Disease (RPD) Designation and Voucher Programs 
Under Section 529 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA will 
award priority review vouchers to sponsors of rare pediatric disease product applications that 
meet certain criteria. Under this program, a sponsor who receives an approval for a drug or 
biologic for a “rare pediatric disease” may qualify for a voucher that can be redeemed to receive 
a priority review of a subsequent marketing application for a different product.
14
 
 
On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was 
extended. Under the current statutory sunset provisions, after September 30, 2024, the FDA may 
only award a voucher for an approved rare pediatric disease product application if the sponsor 
has rare pediatric disease designation for the drug and that designation was granted by September 
30, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority 
review vouchers.
15
 
 
Rare Disease Advisory Council 
In June 2021, the Rare Disease Advisory Council (Council) was created as an adjunct to the 
DOH. The Council comprises representatives from state agencies, health care providers, 
researchers, advocacy groups, insurance, and pharmaceutical industries, as well as individuals 
with rare diseases and caregivers of individuals with rare diseases. Council members hold a 
shared vision: to improve health outcomes for individuals residing in Florida who have rare 
diseases. The Council reports annually to the Governor, Senate President and Speaker of the 
House of Representatives
16
 The DOH is responsible for four research grant programs and will 
implement the proven strategies and processes for awarding highly meritorious grants that will 
support advancements for the prevention, treatment, and cures of pediatric rare diseases.
17
 
 
Newborn Metabolic Screening Program 
The Legislature created the Florida Newborn Screening Program (NBS Program) in 1965 within 
the DOH, to promote the screening of all newborns for metabolic, hereditary, and congenital 
disorders known to result in significant impairment of health or intellect.
18
 The NBS Program 
also promotes the identification and screening of all newborns in the state and their families for 
environmental risk factors such as low income, poor education, maternal and family stress, 
emotional instability, substance abuse, and other high-risk conditions associated with increased 
risk of infant mortality and morbidity to provide early intervention, remediation, and prevention 
services.
19
 
 
The Legislature established the Florida Genetics and Newborn Screening Advisory Council to 
advise the DOH on disorders to be included in the NBS Program panel of screened disorders and 
                                                
14
 United States Food and Drug Administration, Rare Pediatric Disease (RPD) Designation and Voucher Programs, 
available at https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-rpd-
designation-and-voucher-programs (last visited Jan. 31, 2024). 
15
 Id. 
16
 Section 381.99, F.S. 
17
 Supra note 13. 
18
 Section 383.14(1), F.S. 
19
 Id.  BILL: CS/SB 1582   	Page 6 
 
the procedures for collecting and transmitting specimens.
20
 The NBS Program began with the 
screening for phenylketonuria and now screens for 58 conditions prior to discharge. Of the 
conditions screened, 55 conditions are screened through the collection of blood spots. Screening 
of the three remaining conditions – hearing (hearing screening), critical congenital heart defect 
(CCHD) (pulse oximetry) and congenital cytomegalovirus (CMV) targeted screening – are 
completed at the birthing facility through point of care (POC) testing.
21
 
 
The NBS Program involves coordination across several entities, including the Bureau of Public 
Health Laboratories Newborn Screening Laboratory in Jacksonville (state laboratory), The DOH 
Children’s Medical Services (CMS) Newborn Screening Follow-up Program in Tallahassee, 
referral centers, birthing centers, and physicians throughout the state.
22
 Health care providers in 
hospitals, birthing centers, perinatal centers, county health departments, and school health 
programs provide screening as part of the multilevel NBS Program screening process.
23
 This 
includes a risk assessment for prenatal women, and risk factor analysis and screening for 
postnatal women and newborns as well as laboratory screening for select disorders in 
newborns.
24
 The NBS Program attempts to screen all newborns for hearing impairment and to 
identify, diagnose, and manage newborns at risk for select disorders that, without detection and 
treatment, can lead to permanent developmental and physical damage or death.
25
 The NBS 
Program is intended to screen all prenatal women and newborns, however, parents and guardians 
may choose to decline the screening.
26
 
 
Health care providers perform non-laboratory NBS Program screening, such as hearing and risk 
factor analysis, and report the results to the Office of Vital Statistics. If necessary, health care 
providers refer patients to the appropriate health, education, and social services.
27
 
 
Health care providers in hospitals and birthing centers perform specimen collection for 
laboratory analysis for the NBS Program screening by collecting a few drops of blood from the 
newborn’s heel on a standardized specimen collection card.
 28
 The specimen card is then sent to 
the state laboratory for testing and the results are released to the newborn’s health care provider. 
In the event that a newborn screen has an abnormal result, the newborn’s health care 
                                                
20
 Section 383.14(5), F.S. 
21
 Department of Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate 
Committee on Health Policy). 
22
 Section 383.14, F.S. 
23
 Id. 
24
 Id. 
25
 Florida Department of Health, Florida Newborn Screening Guidelines, available at 
https://floridanewbornscreening.com/wp-content/uploads/NBS-Protocols-2022-FINAL.pdf (last visited Jan. 31, 2024). 
26
 Section 383.14(4), F.S.; Fla. Admin. Code R. 64C-7.008, (2023). The health care provider must attempt to get a written 
statement of objection to be placed in the medical record. 
27
 Id. 
28
 Florida Newborn Screening, What is Newborn Screening? available at https://floridanewbornscreening.com/parents/what-
is-newborn-screening/ (last visited Jan. 31, 2024). See also, Florida Newborn Screening, Specimen Collection Card, available 
at http://floridanewbornscreening.com/wp-content/uploads/Order-Form.png (last visited Jan. 31, 2024).  BILL: CS/SB 1582   	Page 7 
 
practitioner,
29
 or a nurse or specialist from the NBS Program’s “Follow-up Program” provides 
follow-up services and referrals for the child and his or her family.
30
 
 
To administer the NBS Program, the DOH is authorized to charge and collect a fee, not to 
exceed $15 per live birth, occurring in a hospital or birth center.
31
 The DOH must calculate the 
annual assessment for each hospital and birth center, and then quarterly generate and mail each 
hospital and birth center a statement of the amount due.
32
 The DOH bills hospitals and birth 
centers quarterly using vital statistics data to determine the amount to be billed.
33
 The DOH is 
authorized to bill third-party payers for the NBS Program tests and bills insurers directly for the 
cost of the screening.
34
 The DOH does not bill families that do not have insurance coverage.
35
 
 
The newborn screening report includes the screening results for all 58 conditions currently 
screened. Newborn screening is part of the standard of care for all infants. Florida law allows for 
a parent to opt-out of newborn screening prior to collection. This opt-out is documented in the 
medical record maintained by the collection facility. The NBS Program maintains the results of 
the newborn screenings, in addition to diagnostic results for newborns identified with a condition 
on the screening panel. Data are available from January 2006 forward. The DOH’s retention 
schedule requires newborn screening records to be permanently maintained.
36
 
 
Newborn Hearing Screening 
Section 383.145, F.S., requires newborn hearing screening for all newborns in hospitals before 
discharge. The newborn hearing screening program (NBHS) is housed within the DOH, which is 
responsible for coordinating the statewide hearing screening and follow-up referral system. The 
NBHS program is funded through a donations trust and federal grants from the federal Centers 
for Disease Control and Prevention and the Health Resources and Services Administration 
(HRSA).
37
 
 
Before a newborn is discharged from a hospital or other state-licensed birthing facility, and 
unless objected to by the parent or legal guardian, the newborn must be screened for the 
detection of hearing loss to prevent the consequences of unidentified disorders.
38
 For births 
occurring in a non-hospital setting, specifically a licensed birth center or private home, the 
facility or attending health care provider is responsible for providing a referral to an audiologist, 
                                                
29
 Current law allows for the screening results to be released to specified health care practitioners including: allopathic and 
osteopathic physicians and physician assistants licensed under chs. 458 and 459, F.S., advanced practice registered nurses, 
registered nurses, and licensed practical nurses licensed under ch. 464, F.S., a midwife licensed under ch. 467, F.S., a speech-
language pathologist or audiologist licensed under part I of ch. 468, F.S., or a dietician or nutritionist licensed under part X of 
ch. 468, F.S. 
30
 Id. 
31
 Section 383.145(3)(g)1., F.S. 
32
 Id. 
33
 Section 383.145(3)(g), F.S. 
34
 Section 383.145(3)(h), F.S.  
35
 Section 383.14, F.S. 
36
 Department of Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate 
Committee on Health Policy). 
37
 Id. 
38
 Section 383.145(3), F.S. If the screening is not completed before discharge due to scheduling or temporary staffing 
limitations, the screening must be completed within 21 days after the birth.  BILL: CS/SB 1582   	Page 8 
 
a hospital, or other newborn hearing screening provider within seven days after the birth or 
discharge from the facility.
39
 
 
All screenings must be conducted by a licensed audiologist, a licensed physician, or 
appropriately supervised individual who has completed documented training specifically for 
newborn hearing screening.
40
 When ordered by the treating physician, screening of a newborn's 
hearing must include auditory brainstem responses, or evoked otoacoustic emissions, or 
appropriate technology as approved by the FDA.
41
 
 
NBHS staff provide follow-up to parents of infants who do not pass the newborn hearing screen 
to ensure timely diagnosis and enrollment in early intervention for children diagnosed with 
hearing loss.
42
 A child who is diagnosed as having a permanent hearing impairment must be 
referred by the licensee or individual who conducted the screening to the primary care physician 
for medical management, treatment, and follow-up services. Furthermore, any child from birth to 
36 months of age who is diagnosed as having a hearing impairment that requires ongoing special 
hearing services must be referred to the Children’s Medical Services Early Intervention Program 
by the licensee or individual who conducted the screening serving the geographical area in which 
the child resides. 
 
Hearing loss is one of the most common birth defects in the U.S., with approximately two 
newborns per 1,000 born having hearing loss each year. It is estimated that only half of early 
childhood hearing loss is detected through newborn hearing screening. To further support early 
identification of hearing loss prior to school entry to prevent the consequences of unidentified 
disorders, the federal Health Resources & Services Administration grants also requires collection 
of hearing screening data for infants and toddlers up to age 36 months.
43
 
 
Sickle Cell Disease 
Sickle cell disease (SCD) affects approximately 100,000 Americans and is the most prevalent 
inherited blood disorder in the U.S.
44
 SCD affects mostly, but not exclusively, persons of African 
ancestry. SCD is a group of inherited disorders in which abnormal hemoglobin cause red blood 
cells to buckle into a sickle shape. The deformed red blood cells damage blood vessels and over 
time contribute to a cascade of negative health effects beginning in infancy, such as intense vaso-
occlusive pain episodes, strokes, organ failure, and recurrent infections.
45
 The severity of 
                                                
39
 Section 383.145(3)(d), F.S. 
40
 Section 383.145(3)(f), F.S. 
41
 Section 383.145(3)(i), F.S. 
42
 .Section 383.14, F.S. 
43
 Id. 
44
 National Institutes of Health ,National Heart, Lung, and Blood Institute, What is Sickle Cell Disease?, available at 
https://www.nhlbi.nih.gov/health/sickle-cell-disease (last visited Jan. 31, 2024). 
45
 Centers for Disease Control and Prevention, What is Sickle Cell Disease? available at 
https://www.cdc.gov/ncbddd/sicklecell/facts.html (last visited Jan. 31, 2024). See also, AHCA (2023) Florida Medicaid 
Study of Enrollees with Sickle Cell Disease. available at 
https://ahca.myflorida.com/content/download/20771/file/Florida_Medicaid_Study_of_Enrollees_with_Sickle_Cell_Disease.p
df (last visited Jan., 2024).  BILL: CS/SB 1582   	Page 9 
 
complications generally worsens as people age, but treatment and prevention strategies can 
mitigate complications and lengthen the lives of people with SCD.
46
 
 
A person who carries a single gene for SCD has sickle cell trait. People with sickle cell trait do 
not have SCD, and under normal conditions they are generally asymptomatic. However, they are 
carriers of SCD and have an increased likelihood of having a child with SCD. It is estimated that 
eight to ten percent of African Americans carry sickle cell trait.
47
 
 
While SCD is the most common inherited blood disorder in the U.S., and is often diagnosed at 
birth through newborn screening programs,
48
 patients with SCD experience many of the other 
trials associated with treating a rare disease. Until recently there was very little research 
development in the areas of managing, treating, or curing SCD.
49
 
 
The NBS Program has included screening for sickle cell disease since 1988. 
 
Sickle Cell Disease Registry 
In 2023, the DOH was required under s. 383.147, F.S., to contract with a community-based 
sickle cell disease medical treatment and research center to establish and maintain a registry for 
newborns and infants who are identified as carrying a sickle cell hemoglobin variant. If a 
screening provider detects that a newborn or an infant is carrying a sickle cell hemoglobin 
variant, it must notify the child’s primary care physician and submit the results to the DOH for 
inclusion in the sickle cell registry The registry must track sickle cell disease outcome measures. 
A parent or guardian of a newborn or an infant in the registry may request to have his or her 
child removed from the registry by submitting a form prescribed by the DOH in rule. 
 
Based on a review of the 2022 provisional data, the DOH identified 137 newborns with SCD and 
5,800 with sickle cell trait. For any newborn identified with sickle cell trait, notification letters 
are sent to both the family and physician on file for each newborn. NBS Program results are 
returned to the submitting provider. It is the responsibility of the submitting entity to forward the 
results to the newborn’s primary care provider.
50
 
 
                                                
46
 Centers for Disease Control and Prevention, Complications of Sickle Cell Disease. available at 
https://www.cdc.gov/ncbddd/sicklecell/complications.html (last visited Jan. 31, 2024). 
47
 American Society of Hematology. ASH Position on Sickle Cell Trait (2021). available at 
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/policy-statements/2021/ash-
position-on-sickle-cell-trait (last visited Jan. 31, 2024). 
48
 Centers for Disease Control and Prevention. Newborn Screening (NBS) Data (2023). available at 
https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-state-data/newborn-
screening/index.html#:~:text=Newborn%20screening%20(NBS)%20for%20sickle,SCD%20living%20in%20a%20state. (last 
visited Jan. 31, 2024). 
49
 See, American Society of Hematology. ASH Sickle Cell Disease Initiative. available at 
https://www.hematology.org/advocacy/sickle-cell-disease-initiative (last visited Jan. 31, 2024). See also Department of 
Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate Committee on Health 
Policy). 
50
 Id.  BILL: CS/SB 1582   	Page 10 
 
Environmental Risk Screening 
In 2022, 223,833 women gave birth in Florida.
51
 Adverse birth outcomes, such as preterm birth 
and low birthweight, are major public health concerns due to the associated risks of morbidity 
and mortality throughout an individual's lifespan.
52,53
 Risk assessment in pregnancy can assist 
with identifying pregnant women who are most likely to experience adverse health events and 
enables providers to administer risk-appropriate prenatal and postnatal care.
54
 Research has also 
shown that the use of risk screening tools significantly reduces risk of low birth weight, preterm 
birth, and fetal and infant morbidity.
55
 Some researchers have found that the risk of low birth 
weight and preterm birth is reduced by as much as thirty percent in underserved communities, 
when a risk screen is completed.
56
 
 
The DOH develops and oversees the prenatal risk screening process to assess for environmental 
risk factors that put a pregnant woman at risk for a preterm birth or other high-risk condition. 
The prenatal risk screen is completed by the pregnant woman’s health care provider at her first 
prenatal appointment. If the prenatal risk screen identifies a pregnant woman is at-risk, she is 
referred to home visiting services, and other services, as necessary, to improve prenatal and birth 
outcomes. 
III. Effect of Proposed Changes: 
Section 1. - Environmental Health Professionals 
The bill amends s. 381.0101, F.S., to create a new profession, the environmental health 
technician (EHT). The bill provides that an EHT is a person employed or assigned the 
responsibility for conducting septic inspections under the supervision of a CEHP. An EHT must 
have completed training approved by the DOH and have the knowledge, skills, and abilities to 
carry out these tasks. 
 
The bill also creates an additional exemption for to the certification requirements in 
s. 381.010(2), F.S., which requires a bachelor’s degree in science for EHTs employed by a 
department
57
 who are assigned the responsibility of conducting septic tank inspections under the 
supervision of a CEHP in onsite sewage treatment and disposal. 
                                                
51
 FloridaHealthCHARTS: Resident Live Births, available at 
https://www.flhealthcharts.gov/ChartsDashboards/rdPage.aspx?rdReport=BirthMonthly.Dataviewer&cid=25 (last visited 
Feb. 1, 2024). 
52
 Risnes KR, Vatten LJ, Baker JL, et al..Birthweight and mortality in adulthood: A systematic review and meta-analysis, Int 
J Epidemiol 2011;40:647–661, available at https://pubmed.ncbi.nlm.nih.gov/21324938/ (last visited Feb. 1, 2024). 
53
 Raju TNK, Pemberton VL, Saigal S, et al.. Long-Term Healthcare Outcomes Of Preterm Birth: An Executive Summary of 
a Conference Sponsored By The National Institutes of Health. J Pediatr 2017;181:309–318.e1. available at 
https://pubmed.ncbi.nlm.nih.gov/27806833/ (last visited Feb. 1, 2024). 
54
 Board on Children, Youth, and Families; Institute of Medicine; National Research Council. (2013). An Update on Research 
Issues in the Assessment of Birth Settings. Workshop Summary. Washington (DC): National Academies Press (US)., 
available at https://www.ncbi.nlm.nih.gov/books/NBK201935/ (last visited Feb. 1, 2024). 
55
 Department of Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate 
Committee on Health Policy). 
56
 Id. 
57
 Section 20.03(8), F.S., defines “department” as the principal administrative unit within the executive branch of state 
government.  BILL: CS/SB 1582   	Page 11 
 
 
The bill requires: 
 The DOH, in conjunction with the DEP, to adopt rules that establish definitions and 
minimum standards of education, training, and experience for the certification of EHTs, and 
the rules must address the following: 
o Education required; 
o Training required; 
o Experience necessary; 
o Application process; 
o Examinations to be taken; 
o Process of certification issuance; 
o Certification expiration; 
o Certification renewal; and 
o Ethical standards of practice for the profession. 
 The DOH to establish standards for an EHT in the areas of onsite sewage treatment and 
disposal; 
 A person conducting septic inspections must be certified by examination to be 
knowledgeable in the area of onsite sewage treatment and disposal; 
 An applicant for certification as an EHT to have received a high school diploma or its 
equivalent; 
 An applicant for certification as an EHT to be employed by a department; 
 An applicant for certification as an EHT to complete supervised field inspection work as 
prescribed by DOH rule before examination; 
 A CEHT to renew his or her certification biennially by completing at least 24 contact hours 
of continuing education for each program area in which he or she maintains certification, 
subject to a maximum of 48 hours for multi-program certification; and 
 A CEHT to notify the DOH within 60 days after any change of name or address from that 
which appears on the current certificate. 
 
According to the DOH, an EHT could perform septic inspections, like a CEHP, but the 
technician would not be required to have a four-year college degree with certain scientific 
coursework to be eligible for this certification examination. Technicians would be required to 
complete an amount of observed field work set by rule, attain a passing score on the certification 
test, and meet any additional rule requirements. Regulatory work, would include approving 
permits, and the technician’s work would be subject to the supervision and approval of his or her 
supervising CEHP.
58
 
 
Section 2. - Andrew John Anderson Pediatric Rare Disease Grant Program 
The bill creates the Andrew John Anderson Pediatric Rare Disease Grant Program within the 
DOH under s. 381.991, F.S. The purpose of the grant program is to advance the progress of 
research and cures for rare pediatric diseases by awarding grants through a competitive, peer-
reviewed process. Subject to an annual appropriation by the Legislature, the program must award 
                                                
58
 Department of Health, 2024 Agency Legislative Bill Analysis, SB 1582 (Sept. 18, 2023) (on file with the Senate 
Committee on Health Policy).  BILL: CS/SB 1582   	Page 12 
 
grants for scientific and clinical research to further the search for new diagnostics, treatments, 
and cures for rare pediatric diseases. 
 
The bill requires that: 
 Applications for the grants may be submitted by any university or established research 
institute in Florida and that all qualified investigators, regardless of institutional affiliation, 
will have equal access and opportunity to compete for funding; 
 The grants may be awarded by the DOH after consultation with the Rare Disease Advisory 
Council on the basis of scientific merit, as determined by the competitive, peer-reviewed 
process to ensure objectivity, consistency, and high quality; 
 The DOH must appoint peer review panels of independent, scientifically qualified 
individuals to review the scientific merit of each proposal and establish its priority score to 
ensure appropriate and fair evaluation of grant applications based on scientific merit; 
 The priority scores must be forwarded to the council and must be considered in determining 
which proposals will be recommended for funding; and 
 The council and the peer review panels must establish and follow rigorous guidelines for 
ethical conduct and adhere to a strict policy with regard to conflicts of interest. 
 
The bill authorizes: 
 The use of preferences for grant proposals that foster collaboration among institutions, 
researchers, and community practitioners, on the basis that as such proposals support the 
advancement of treatments and cures of rare pediatric diseases through basic or applied 
research; 
 The following types of applications to be considered for funding: 
o Investigator-initiated research grants; 
o Institutional research grants; and 
o Collaborative research grants, including those that advance the finding of treatment and 
cures through basic or applied research. 
 The balance of any Legislative appropriation for the Grant Program that is not disbursed, but 
is obligated pursuant to contract or committed to be expended by June 30 of the fiscal year in 
which the funds were appropriated, to be carried forward for up to five years after the 
effective date of the original appropriation. 
 
The bill prohibits any council or panel member from participating in any discussion or decision 
of the council or panel with respect to a research proposal by any firm, entity, or agency that the 
member is associated with as a member of the governing body or as an employee or with which 
the member has entered into a contractual arrangement. 
 
Section 3. - Newborn Metabolic Screening Program 
The bill amends s. 383.14, F.S., to require that any health care practitioner present at a birth or 
responsible for primary care during the neonatal period has the primary responsibility of 
administering newborn screenings as required in ss. 383.14 and 383.145, F.S. The bill defines the 
term “health care practitioner” to mean physicians or physician assistants (PAs) licensed under 
chs. 458 or 459, F.S., advanced practice registered nurses (APRNs) licensed under ch. 464, F.S, 
and a midwife licensed under ch. 467, F.S., and requires those practitioners to prepare and send 
all newborn screening specimen cards to the State Public Health Laboratory.  BILL: CS/SB 1582   	Page 13 
 
 
The bill removes language related to risk screening for environmental risk factors from s. 383.14, 
F.S., and relocates it to s. 383.148, F.S., later in the bill. The bill also repeals the following: 
 Obsolete requirements for the NBS Program and Healthy Start to coordinate with the Florida 
Department of Education (DOE) for consultation; and 
 Language referencing the initial newborn screening condition (phenylketonuria) and multiple 
other screening methods to allow the NBS Program to apply principles to all conditions on 
the NBS Program screening panel. 
 
The bill authorizes: 
 Licensed genetic counselors to receive NBS Program results; 
 The NBS Program to implement systemic improvements for diagnostic reporting and 
submission of NBS Program specimens and point of contact screening results. 
 
Section 4. - Newborn Hearing Screening 
The bill amends s. 383,145, F.S., to add the definition of “toddler” to mean a child from 12 
months to 36 months of age. The bill requires that: 
 Both infants and toddlers are added to the hearing screening program when a treating 
physician orders a hearing screening which must include auditory brainstem responses, or 
evoked otoacoustic emissions, or appropriate technology as approved by the FDA;  
 All licensed birth centers that provide maternity and newborn care services must ensure that 
all newborns are, before discharge, screened for the detection of hearing loss and that within 
seven days after the birth, the licensed birth center must ensure that all newborns who do not 
pass the hearing screening are referred for an appointment for a test to screen for congenital 
cytomegalovirus (CMV) before the newborn becomes 21 days of age; and 
 For home births, the newborn’s primary health care provider must refer the newborn for 
administration of a test approved by the FDA or another diagnostically equivalent test on the 
newborn to screen for congenital CMV before the newborn becomes 21 days of age. 
 
Section 5 – Sickle Cell Disease Registry 
The bill amends s. 383.147, F.S., to provide that: 
 If a newborn is identified as having sickle cell disease or carrying a sickle cell trait through 
the NBS Program, the results will be included in the statewide SCD registry unless the parent 
or guardian provides an opt-out form obtained from the DOH, or otherwise indicates in 
writing of his or her objection to having the newborn included in the registry; and 
 Persons living in this state who have been identified as having sickle cell disease or carrying 
a sickle cell trait may choose to be included in the registry by providing the DOH with 
notification as prescribed by rule. 
 
Section 6 – Environmental Risk Screening 
The bill creates s. 383.148, F.S., to house the DOH’s requirements relating to screening pregnant 
women and infants in this state for environmental risk factors, which are being relocated to this 
new statute from s. 383.14, F.S. 
  BILL: CS/SB 1582   	Page 14 
 
The bill also amends ss. 383.318, 395.1053, and 456.0496, F.S., to make conforming cross 
reference changes. 
 
The bill provides an effective date of July 1, 2024. 
IV. Constitutional Issues: 
A. Municipality/County Mandates Restrictions: 
None. 
B. Public Records/Open Meetings Issues: 
None. 
C. Trust Funds Restrictions: 
None. 
D. State Tax or Fee Increases: 
None. 
E. Other Constitutional Issues: 
None. 
V. Fiscal Impact Statement: 
A. Tax/Fee Issues: 
None. 
B. Private Sector Impact: 
None. 
C. Government Sector Impact: 
According to the DOH, The Rare Pediatric Disease Research Program is currently funded 
at $500,000. This funding will be used exclusively for research grants. To assure the 
proper evaluation of the research grants, peer reviewers will be required. 
VI. Technical Deficiencies: 
None.  BILL: CS/SB 1582   	Page 15 
 
VII. Related Issues: 
A child’s SCD test results are required to be automatically included in the statewide SCD 
registry under current law. On lines 672-688, the bill allows a parent or guardian to opt-out of 
having a child’s SCD test results included in the registry by submitting an opt-out form 
“obtained from the department” or by otherwise indicating in writing to the DOH of his or her 
objections to having the child included in the registry. However, there is no requirement in the 
opt-out procedure created by the bill for the parent or guardian to be informed of the existence of 
the opt-out form or of his or her ability to opt-out. 
VIII. Statutes Affected: 
This bill substantially amends the following sections of the Florida Statutes: 381.0101, 383.14, 
383.145, 383.147, 383.318, 395.1053, and 456.0496. 
 
This bill creates the following sections of the Florida Statutes: 381.991 and 383.148. 
IX. Additional Information: 
A. Committee Substitute – Statement of Substantial Changes: 
(Summarizing differences between the Committee Substitute and the prior version of the bill.) 
CS by Health Policy on February 6, 2024: 
The committee substitute removes the Telehealth Minority Maternity Care Program from 
the bill. 
B. Amendments: 
None. 
This Senate Bill Analysis does not reflect the intent or official position of the bill’s introducer or the Florida Senate.